RBC Capital Upgrades Auxilium Pharmaceuticals (AUXL) to Outperform

RBC Capital upgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Sector Perform to Outperform, price target raised from $20 to $26.

For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.

Shares of Auxilium Pharmaceuticals closed at $19.73 yesterday, with a 52 week range of $13.59-$25.10.

---

Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
• Willis Group (WSH) Shares Edge Higher Following Macquarie Upgrade
• MKM Partners Upgrades Auxilium Pharmaceuticals (AUXL) to Buy

Create E-mail Alert Related Categories

Upgrades

Related Entities

RBC Capital

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter